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Combined pulmonary fibrosis and emphysema (CPFE) is one of smoking-related lung 
diseases. 
Emphysema is characterized by the permanent abnormal enlargement of airspaces distal to the 
terminal bronchioles, accompanied by destruction of their walls. The characteristics of 
emphysema do not, by definition, include thickening of the alveolar septa and fibrosis. 
However, coincidental idiopathic pulmonary fibrosis (IPF) and emphysema was firstly 
reported in 1990 by Wiggins et al (Wiggins J, et al., 1990) in London. Smoking-related 
interstitial lung diseases (SRILD) include desquamative interstitial pneumonia (DIP), 
respiratory bronchiolitis-related interstitial lung disease (RB-ILD), pulmonary Langerhans’ cell 
histiocytosis (LCH) and idiopathic pulmonary fibrosis (IPF) (Ryu JH, et al., 2001). Tobacco 
smoking is also major course of emphysema and chronic obstructive pulmonary disease 
(COPD). Smoking is a common risk factor for both emphysema and pulmonary fibrosis. 
Recently, the occurrence of both emphysema and pulmonary fibrosis in the same patient has 
received increased attention as the syndrome of combined pulmonary fibrosis and 
emphysema (CPFE) (Cottin V, et al., 2005). It has been demonstrated that CPFE syndrome is 
not rare because on a series of 110 patients with IPF, 28% of them with at least 10% of the lung 
affected with emphysema, and thus are considered to have CPFE (Mejia M, et al., 2009).  
2. Clinical characteristics of CPFE 
In Japan Hiwatari et al (Hiwatari N, et al., 1993) reported nine patients with pulmonary 
emphysema and IPF among 152 pulmonary emphysema patients in 1993. Those patients 
were all men and heavy smokers. Odani et al (Odani K, et al., 2004) reported 31 patients 
combined with pulmonary emphysema and IPF among 14900 patients who underwent chest 
CT from January 1996 to March 2001 at Kochi Medical School Hospital in Japan. The CT of 
all patients showed the coexistence of emphysema with upper lung field predominance and 
diffuse parenchymal lung disease with significant pulmonary fibrosis predominantly in the 






patients and paraseptal emphysema in 11 of 31 patients (35%). Honeycombing, which is one 
of the most common findings of usual interstitial pneumonia, was present in 24 of the 31 
patients (77%). In 2005 Cottin et al (Cottin V, et al., 2005) conducted a retrospective study of 
61 patients with CPFE and characterized this association as a distinct entity. They reported 
that sixty patients were male, dyspnea on exertion was present in all patients, basal crackles 
were found in 87% and finger clubbing in 43%. Pulmonary function tests showed preserved 
lung volumes and strongly impaired lung diffusing capacity for carbon monoxide (DLCO). 
They showed that pulmonary hypertension was frequent in patients with CPFE with 47% of 
patients with estimated systolic right ventricular pressure ≧45 mmHg at echocardiography 
and the 5-yr probability of survival was 25% in patients with pulmonary hypertension 
compared with 75% in those without pulmonary hypertension at diagnosis (Figure 2). They 
also confirmed these findings by right heart catheterization on a retrospective multicenter 
study and concluded that the patients with CPFE and pulmonary hypertension have a 
dismal prognosis despite moderately altered lung volume and flows (Cottin V, et al., 2010). 
The risk of developing pulmonary hypertension is much higher in CPFE than in IPF without 
emphysema (Mejia M, et al., 2009). Pulmonary hypertension was a critical determinant of 
the prognosis.  
 
Fig. 1. Imaging in a 66-year-old male with combined pulmonary fibrosis and emphysema 
(CPFE). Chest high-resolution computed tomography of the bilateral upper lung fields (a) 
shows centriaciner + paraseptal emphysema with thick walled bulla and of the bilateral 
lower lung fields (b) shows reticular opacities and traction bronchiectasis. 
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Fig. 2. Total survival of patients with combined pulmonary fibrosis and emphysema (CPFE) 
(a); 5-yr survival was 55%. Survival for subjects with CPFE stratified on the basis of 
pulmonary hypertension (PH) (b); 5-yr survival was significantly less in patients with 
pulmonary hypertension (25%) compared with those without pulmonary hypertension 
(75%) at diagnosis. 
We retrospectively examined the clinical characteristics of 47 patients with CPFE based on 
the findings of chest HRCT consecutively recruited from outpatients attending Shinshu 
University Hospital between October 2004 and June 2007 (Kitaguchi Y, et al., 2010). The 
clinical characteristics of CPFE patients were compared with those of emphysema-dominant 
COPD patients without parenchymal lung disease (COPD without fibrosis). Forty-six of the 
47 CPFE patients were male. Paraseptal emphysema was particularly common in the CPFE 
group, although centriacinar was dominant in the COPD without fibrosis (Table 1). All 
CPFE patients showed the coexistence of emphysema with upper lung fields predominance 






fields predominance. Honeycombing, ground-glass opacities and reticular opacities were 
present in 75.6%, 62.2% and 84.4% of CPFE patients, respectively. Thick-walled bullae were 
characteristic in CPFE and observed in more than one half of the CPFE patients. 
Twenty-seven of the 47 CPFE patients (57.4%) showed a FEV1/FVC ratio within the normal 
range and the other patients showed milder airflow limitation, although the presence of 
severe emphysema (Table 2, 3). All CPFE patients showed lower lung volume and DLCO 
than the patients with COPD without fibrosis as previously reported. Desaturation during 
6-min walking test in CPFE patients tended to be more severe than in COPD without 
fibrosis patients, if the level of FEV1 or 6-minute walking distance was equal (Figure 3). 
These findings suggest that CPFE patients show severe dyspnea and severe hypoxemia on 
effort in spite of subnormal spirometry findings. 
 CPFE COPD 
LAA score  13.2±0.9** 18.9±0.7 
Upper lobe  5.6±0.3** 6.7±0.2 
Middle lobe  4.3±0.3** 6.2±0.2 
Lower lobe  3.3±0.4** 5.9±0.3 
Emphysema type   
centriacinar, %  11 (24.4%)** 49 (59.8%) 
panacinar＋centriacinar, %  7 (15.6%)* 26 (31.7%) 
paraseptal, %  15 (33.3%)** 7 (8.5%) 
paraseptal＋centriacinar, %  12 (26.7%)** 0 (0.0%) 
IP distribution   
Upper lobe  8 (17.0%)  
Middle lobe  18 (38.3%)  
Lower lobe  47 (100.0%)  
IP pattern   
Thick-walled bulla, n (%)   26 (57.8%)  
honeycombing, n (%) 34 (75.6%)  
reticular opacity, n (%)  38 (84.4%)  
ground glass opacity, n (%) 28 (62.2%)  
consolidation, n (%)  6 (13.3%)  
traction bronchiectasis, n (%) 18 (40.0%)  
peribronchovascular thickening, n (%)  4 (8.9%)  
architectural distortion, n (%) 7 (15.6%)  
Values are the mean±SEM． *p<0.05 and **p<0.01 vs. COPD. 
Table 1. Chest HRCT findings in patients with combined pulmonary fibrosis and 
emphysema (CPFE, n=47) and emphysema dominant COPD without fibrosis (COPD, n=82). 
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Sex, female/male 1/46 8/74
Body mass index, kg/m2 22.9±0.4** 20.5±0.3 
Smoking history, packs・year 58.7±4.4 59.4±3.0 
Non-COPD 27 (57.4%) 0 (0.0%) 
COPD 20 (42.6%) 82 (100.0%) 
Stage˧ 8 (17.0%) 8 (9.8%) 
Stage˨ 8 (17.0%)** 34 (41.5%) 
Stage˩ 4 (8.5%)** 30 (36.6%) 
Stage˪ 0 (0.0%)* 10 (12.2%) 
Complication of lung cancer、n (%) 22 (46.8%)** 6 (7.3%) 
squamous cell carcinoma 12 (54.5%)** 3 (50.0%) 
small cell carcinoma 2 (9.1%) 0 (0.0%) 
adenocarcinoma 7 (31.8%) 3 (50.0%) 
LCNEC 1 (4.5%) 0 (0.0%) 
n (%), Values are the mean±SEM． *p<0.05 and **p<0.01 vs. COPD. 
Table 2. Clinical characteristics in patients with combined pulmonary fibrosis and 
emphysema (CPFE) and emphysema dominant COPD without fibrosis (COPD). 
 CPFE COPD
%VC, %  94.7±3.5 96.6±2.4
FEV1, % of pred. 79.0±3.1** 54.7±2.7
FEV1/FVC, %  71.8±2.0** 48.0±1.2
FRC, % of pred. 89.9±5.8** 112.5±2.7
RV, % of pred.  114.7±10.3** 181.7±5.5
RV/TLC, %  37.3±1.9** 50.5±1.1
%DLco, %  39.6±2.5** 57.7±2.2
PaO2, torr  68.6±2.3 70.0±1.3
PaCO2, torr  39.3±0.9 40.5±0.6
α1-AT, mg/dl  153±15 190±38
CRP, mg/dl  1.1±0.3 0.5±0.1
KL-6, U/ml  1058±166 -
Values are the mean±SEM． **p<0.01 vs. COPD. 
Table 3. Pulmonary function tests and laboratory data in patients with combined pulmonary 








Fig. 3. Relationship between ΔSpO2 during a 6-minute walking test and FEV1 or 6 minute-
walking distance (6MWD) in patients with combined pulmonary fibrosis and emphysema 
(CPFE) and emphysema dominant COPD without fibrosis (COPD). 
3. Higher incidence of lung cancer 
In the series of our retrospective study, twenty-two of the 47 CPFE patients (46.8%) had lung 
cancer whereas only 7.3% of the patients with COPD without fibrosis had (Table 2) 
(Kitaguchi Y, et al., 2010). There were no significant differences in histological type of cancer 
between CPFE and COPD without fibrosis group. Odani et al (Odani K, et al., 2004) also 
reported higher incidence of lung cancer and 42% (13 patients) of CPFE were complicated 
lung cancer as well as our report and squamous cell carcinoma was the most common 
histological type. On the other hand, Nakayama et al reported that 18 of 127 patients with 
COPD (14%) were complicated with lung cancer in Japan (Nakayama M, et al., 2003). 
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According to a clinical study of IPF based on autopsy studies in elderly patients performed 
in Japan, lung cancer developed in approximately 23% of the IPF patients (Araki T, et al., 
2003). Therefore, the complicated ratio of lung cancer might be higher in CPFE patients than 
in COPD and IPF patients. However, the evidence is poor because of retrospective study 
and a single institution study may have some selection bias. Further investigations are 
needed to clarify whether CPFE is an independent risk factor for lung cancer, its role in 
susceptibility to lung cancer.  
 
Fig. 4. Imaging in a 78-year-old male with CPFE complicated with lung cancer (squamous 
cell carcinoma) in the left lung S4. Chest HRCT images before left upper lobectomy (A, B) 
and after upper lobectomy (C, D). Two months later, the patients developed exacerbation of 
interstitial pneumonia, new diffuse bilateral ground-glass opacities superimposed on a 
background of reticular opacities and honeycombing with basal and peripheral 
predominance (E, F).  
When the patients with CPFE are complicated with lung cancer, it may have a profound 
influence on their prognosis because of poor operability and difficulties in chemotherapy. 






cancer. CPFE, emphysema and fibrosis were identified in 8.9%, 35.3% and 1.3% patients 
with lung cancer, retrospectively. The median overall survival of CPFE patients was 
significantly less than that of normal patients or that of patients with emphysema alone. Of 
interest, 76% of lung cancers in patients with CPFE were diagnosed at an advanced stage. 
Also, fatal severe acute lung injury occurred more frequently (19.8%) in CPFE, irrespective 
of the treatment modality. Especially, postoperative lung injury occurred in nine of 33 
patients with CPFE. Therefore, the presence of CPFE may be higher risk for postoperative 
lung injury as well as the presence of interstitial lung disease (Chiyo M, et al., 2003). Figure 4 
shows imaging in a 78-year-old male with CPFE complicated with lung cancer (squamous 
cell carcinoma) in the segment 4 of left lung admitted to our hospital. He was underwent left 
upper lobectomy for lung cancer. However, two months later, he developed severe 
exacerbation of interstitial pneumonia, and dies due to respiratory failure. 
4. Pathogenesis 
Little is known about the pathogenesis of CPFE. Concerning with parenchymal lung disease 
in CPFE, usual interstitial pneumonia (UIP) has been the most common histopathological 
finding, and there are no differences in histological findings from IPF. IPF and pulmonary 
emphysema have distinct clinical and pathological characteristics, and have been considered 
to be separate disorders. In spite of such differences, animal experiments have suggested 
that the same lung injury might result in either fibrosis or emphysema. Connective tissue 
synthesis during the healing phase may be the critical determinant (Niewoehner DE, et al., 
1982). Hoyle et al. (Hoyle GW, et al., 1999) reported that the overexpression of platelet-
derived growth factor-B induced both emphysema and fibrotic lung disease in the 
developing and adult lung of transgenic mice. It has been also shown that the 
overexpression of TNF-alpha driven by the surfactant protein C promoter (Lundblad LK, et 
al., 2005), IL-13 (Fulkerson PC, et al., 2006), and transforming growth factor-beta 1 (Lee CG, 
et al., 2006) in transgenic mice induces pathological changes consistent with both 
emphysema and pulmonary fibrosis. These pathological changes might represent an 
experimental animal model of CPFE. The tissue effects of these factors might depend on the 
balance of apoptosis, proteolysis and fibrosis and might regulate the degree of emphysema 
and/or fibrosis in the injured lung. It has been recently reported a 32-year-old women, 
never smokers, with CPFE and her daughter at 3 months of age showed having fibrosing 
interstitial pneumonia, and both the mother and daughter had a mutation of the surfactant 
protein-C (SFTPC) gene (Cottin V, et al., 2011). It is suggested that an individual’s genetic 
background may predispose some smokers to the development of CPFE. Further studies are 
needed to elucidate these phenomena. 
5. Conclusion 
CPFE patients had some different clinical characteristics in comparison with emphysema 
and interstitial lung disease and should be included as a smoking-related lung disease. The 
patients with CPFE show severe dyspnea, unexpected subnormal spirometry findings, 
severely impaired DLCO, hypoxemia at exercise, characteristic imaging feature, and a high 
probability of severe pulmonary hypertension and lung cancer. A strict follow-up is 
therefore required because of higher rate of complicated pulmonary hypertension and lung 
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cancer and acute exacerbation may occur after lung surgery in CPFE. HRCT plays an 
important role in diagnose CPFE and evaluating the occurrence of lung cancer and an acute 
exacerbation of CPFE. CPFE syndrome is an important entity and is a matter of growing 
interest by respiratory clinicians.  
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